CSTI-500 10mg for Prader-Willi Syndrome

"Limited efficacy and safety data means CSTI-500 10mg only receives a score of 1 on Power's scale. This is because the drug is currently in Phase 1 trials."

"This trial is available to patients between 13 and 50 years of age. Evidently, there are more clinical trials for individuals over 65 (984) than those under 18 (376)."

"Affirmative. According to clinicaltrials.gov, this research study is currently in the process of enlisting participants. Having been posted on November 14th 2022 and most recently edited on the same date, only 14 volunteers are needed from a single medical site."

"This medical experiment requires 14 people living with Royer Syndrome, aged between 13 and 50. Eligibility is contingent on the following qualifiers: male or female subjects (13-50 years of age at screening); those who have had PWS medically confirmed via genetic testing; no pregnancy or lactation in females, necessitating dual barrier contraception throughout participation; a normal supine systolic pressure ≤140mmHg & ≥100 mmHg and diastolic pressure ≤80mmHg & ≥60 mmHg measured during screening; pulse rate must be within acceptable range, i.e., ≥50bpm to ≤100"

"Affirmative. According to records available on clinicaltrials.gov, this experiment is presently looking for 14 willing participants from 1 centre. The trial was initially published on November 14th 2022 and has since been updated according to the same date."